Search details
1.
Progress report of a cross-organ and biomarker-based basket-type clinical trial: BELIEVE Trial.
Cancer Sci
; 115(2): 555-563, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38041215
2.
Identification of barriers to implementation of precision oncology in patients with rare cancers.
Cancer Sci
; 115(6): 2023-2035, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38538548
3.
Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants.
N Engl J Med
; 384(1): 42-50, 2021 01 07.
Article
in English
| MEDLINE | ID: mdl-33406329
4.
A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors.
Invest New Drugs
; 2024 Jun 04.
Article
in English
| MEDLINE | ID: mdl-38833067
5.
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer.
Invest New Drugs
; 2024 Mar 26.
Article
in English
| MEDLINE | ID: mdl-38530565
6.
Pimitespib for the treatment of advanced gastrointestinal stromal tumors and other tumors.
Future Oncol
; 20(9): 507-519, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38050698
7.
Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort study.
Jpn J Clin Oncol
; 54(2): 175-181, 2024 Feb 07.
Article
in English
| MEDLINE | ID: mdl-37899139
8.
Platform trial for off-label oncology drugs using comprehensive genomic profiling under the universal public healthcare system: the BELIEVE trial.
Int J Clin Oncol
; 29(2): 89-95, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38112833
9.
Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study.
Int J Clin Oncol
; 29(4): 386-397, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38381163
10.
First-in-human study of ONO-4578, an antagonist of prostaglandin E2 receptor 4, alone and with nivolumab in solid tumors.
Cancer Sci
; 114(1): 211-220, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36082616
11.
Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight.
Cancer Sci
; 114(5): 2087-2097, 2023 May.
Article
in English
| MEDLINE | ID: mdl-36704833
12.
Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
Br J Cancer
; 129(12): 2003-2013, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37731022
13.
Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations.
Cancer Immunol Immunother
; 72(8): 2613-2621, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37062033
14.
Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study.
Invest New Drugs
; 41(1): 1-12, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36331674
15.
Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials.
Invest New Drugs
; 41(1): 173-181, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36471215
16.
A new era of the Asian clinical research network: a report from the ATLAS international symposium.
Jpn J Clin Oncol
; 53(7): 619-628, 2023 Jun 29.
Article
in English
| MEDLINE | ID: mdl-37099440
17.
A multi-centre, double-blind, randomized, placebo-controlled trial to evaluate the effectiveness and safety of ramelteon for the prevention of postoperative delirium in elderly cancer patients: a study protocol for JORTC-PON2/J-SUPPORT2103/NCCH2103.
Jpn J Clin Oncol
; 53(9): 851-857, 2023 Aug 30.
Article
in English
| MEDLINE | ID: mdl-37340766
18.
Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice.
Cancer Sci
; 113(12): 4300-4310, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36106376
19.
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression.
Cancer Immunol Immunother
; 71(3): 737-746, 2022 Mar.
Article
in English
| MEDLINE | ID: mdl-34389874
20.
Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab.
Cancer Immunol Immunother
; 71(2): 387-398, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-34180007